Preliminary results of the first-in-human, dose-finding PROCLAIM-CX-072 trial of the PD-L1 Probody therapeutic CX-072 as monotherapy in patients (pts) with advanced solid tumors
| Autor: | Mark Stroh, Karen A. Autio, Matthias Will, Rachel Humphrey, Beiyao Zheng, Valentina Boni, James Strauss, Johanna C. Bendell, Luc R. Desnoyers, Amy Weise, Naiyer A. Rizvi, Bert H. O'Neil, Alexander I. Spira, Nataliya Volodymyrivna Uboha, Lori Carman, Anthony B. El-Khoueiry, Aung Naing, Hendrik-Tobias Arkenau |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Cancer Research
biology business.industry First in human 030226 pharmacology & pharmacy Programmed cell death ligand 1 03 medical and health sciences Dose finding 0302 clinical medicine Oncology 030220 oncology & carcinogenesis PD-L1 biology.protein Cancer research Medicine In patient Antibody business |
| Zdroj: | Journal of Clinical Oncology. 36:3071-3071 |
| ISSN: | 1527-7755 0732-183X |
| Popis: | 3071Background: In single-agent trials, antibodies (Abs) targeting programmed cell death ligand 1 (PD-L1) improve survival in many cancers but are associated with immune-related toxicities (most co... |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|